New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
08:50 EDTAPRIApricus Biosciences ceases financing of French subsidiaries
Apricus Biosciences announced that it intends to cease financing its French subsidiaries, Finesco SAS, its French holding company, Scomedica SAS, its French sales company and NexMed Pharma SAS its marketing company. In line with its previously stated corporate strategy, the company will continue to focus its resources on commercializing its lead product Vitaros, for the treatment of erectile dysfunction, or ED, and on further developing through clinical trials it lead product candidate, Femprox, for the treatment of female sexual arousal disorder, or FSAD. The strategic decision to cease financing its French subsidiaries follows a decrease in the unit's operating performance resulting from recently enacted pricing policies affecting drug reimbursement in France and the subsequent, related loss or interruption of certain contract sales agreements. Given these events, the company re-assessed the fair value of the reporting unit of the French subsidiaries and as a result of that assessment, the company recorded one-time, non-cash, impairment charges totaling approximately $8.8M in 4Q12.
News For APRI From The Last 14 Days
Check below for free stories on APRI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:35 EDTAPRIApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 12, 2014
07:28 EDTAPRIApricus Biosciences files $100M mixed securities shelf
Subscribe for More Information
07:07 EDTAPRIAspire Capital purchases 1.16M shares of Apricus Biosciences for $2M
Subscribe for More Information
07:05 EDTAPRIApricus Biosciences reports Q2 EPS 5c, consensus (4c)
Reports Q2 revenue $5.5M, consensus $5.45M.
August 8, 2014
07:36 EDTAPRIApricus Biosciences announces multi-year partnership with SRF
Apricus Biosciences announced a multi-year partnership agreement with the Scleroderma Research Foundation, or SRF, to support the foundation's activities and the further progress of SRF's groundbreaking research programs. As part of the partnership, Apricus will co-sponsor an upcoming Scleroderma Research Roundtable Series and plans to participate in SRF's Annual Scientific Workshop and an SRF-sponsored event to take place at the upcoming American College of Rheumatology 2014 Annual Meeting. Apricus' product candidate for the treatment of Raynaud's phenomenon, RayVa, is expected to begin a phase 2a clinical trial in the second half of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use